Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis.

Lu YT, Chang PH, Chen HJ, Hsueh YW, Chang CW, Hsu HC, Yang TC, Lin WC, Chang HM

Diabetes, obesity & metabolism9 Jan 2026Cited by 6 (Europe PMC)

PMID41508932DOI10.1111/dom.70452PepBankPUB-41508932

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In overweight or obese women with PCOS, pooled liraglutide-alone or liraglutide-combination interventions increased menstrual frequency versus control treatments (g 1.76; 95% CI 0.28-3.24), with high heterogeneity.
In plain wordsIn overweight or obese women with PCOS, pooled liraglutide-alone or combination interventions increased menstrual frequency versus controls; heterogeneity was high.
Peptide
Liraglutide
Outcome
IncreaseMenstrual frequency
Study
n: not reported in source
Comparator
Control treatments
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Hedges' g
1.76
menstrual frequency
Source sentences
Summary
Compared with control treatments, liraglutide significantly increased menstrual frequency (g = 1.76; 95% CI [0.28, 3.24])
3 context sentences(design, population, supporting numbers)
Summary · context
Heterogeneity was high for menstrual frequency.
Summary · context
PubMed, Embase, the Cochrane Library, Scopus, Web of Science and ClinicalTrials.gov were systematically searched from inception to 31 May 2025 for randomized controlled trials (RCTs) comparing liraglutide (alone or in combination) with placebo, metformin or non-liraglutide active treatments in overw…
Summary · context
Seven RCTs comprising 330 women with PCOS were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4150893201
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In overweight or obese women with PCOS, pooled liraglutide interventions alone or in combination reduced body mass index versus control treatments.
In plain wordsIn overweight or obese women with PCOS, pooled liraglutide-alone or combination interventions reduced body mass index versus controls.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Comparator
Control treatments
Outcome group
Body weight · Metabolic and weight
Measurements
Hedges' g
−0.52
body mass index
Source sentences
Summary
reduced body mass index (BMI; g = -0.52; [-0.94, -0.10])
3 context sentences(design, population, supporting numbers)
Summary · context
Compared with control treatments, liraglutide significantly increased menstrual frequency (g = 1.76; 95% CI [0.28, 3.24])
Summary · context
PubMed, Embase, the Cochrane Library, Scopus, Web of Science and ClinicalTrials.gov were systematically searched from inception to 31 May 2025 for randomized controlled trials (RCTs) comparing liraglutide (alone or in combination) with placebo, metformin or non-liraglutide active treatments in overw…
Summary · context
Seven RCTs comprising 330 women with PCOS were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4150893202
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In overweight or obese women with PCOS, pooled liraglutide interventions alone or in combination improved insulin resistance versus control treatments.
In plain wordsIn overweight or obese women with PCOS, pooled liraglutide-alone or combination interventions improved insulin resistance versus controls.
Peptide
Liraglutide
Outcome
DecreaseInsulin resistance
Study
n: not reported in source
Comparator
Control treatments
Outcome group
Glycemic control · Metabolic and weight
Measurements
Hedges' g
−0.52
HOMA-IR
Source sentences
Summary
improved insulin resistance (homeostatic model assessment of insulin resistance; g = -0.52; [-0.83, -0.22])
3 context sentences(design, population, supporting numbers)
Summary · context
Compared with control treatments, liraglutide significantly increased menstrual frequency (g = 1.76; 95% CI [0.28, 3.24])
Summary · context
PubMed, Embase, the Cochrane Library, Scopus, Web of Science and ClinicalTrials.gov were systematically searched from inception to 31 May 2025 for randomized controlled trials (RCTs) comparing liraglutide (alone or in combination) with placebo, metformin or non-liraglutide active treatments in overw…
Summary · context
Seven RCTs comprising 330 women with PCOS were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4150893203
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In overweight or obese women with PCOS, pooled liraglutide interventions alone or in combination lowered luteinizing hormone versus control treatments.
In plain wordsIn overweight or obese women with PCOS, pooled liraglutide-alone or combination interventions lowered luteinizing hormone versus controls.
Peptide
Liraglutide
Outcome
DecreaseLuteinizing hormone
Study
n: not reported in source
Comparator
Control treatments
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
lowered luteinizing hormone and free androgen index
3 context sentences(design, population, supporting numbers)
Summary · context
Compared with control treatments, liraglutide significantly increased menstrual frequency (g = 1.76; 95% CI [0.28, 3.24])
Summary · context
PubMed, Embase, the Cochrane Library, Scopus, Web of Science and ClinicalTrials.gov were systematically searched from inception to 31 May 2025 for randomized controlled trials (RCTs) comparing liraglutide (alone or in combination) with placebo, metformin or non-liraglutide active treatments in overw…
Summary · context
Seven RCTs comprising 330 women with PCOS were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4150893204
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In overweight or obese women with PCOS, pooled liraglutide interventions alone or in combination lowered free androgen index versus control treatments.
In plain wordsIn overweight or obese women with PCOS, pooled liraglutide-alone or combination interventions lowered free androgen index versus controls.
Peptide
Liraglutide
Outcome
DecreaseFree androgen index
Study
n: not reported in source
Comparator
Control treatments
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
lowered luteinizing hormone and free androgen index
3 context sentences(design, population, supporting numbers)
Summary · context
Compared with control treatments, liraglutide significantly increased menstrual frequency (g = 1.76; 95% CI [0.28, 3.24])
Summary · context
PubMed, Embase, the Cochrane Library, Scopus, Web of Science and ClinicalTrials.gov were systematically searched from inception to 31 May 2025 for randomized controlled trials (RCTs) comparing liraglutide (alone or in combination) with placebo, metformin or non-liraglutide active treatments in overw…
Summary · context
Seven RCTs comprising 330 women with PCOS were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4150893205
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In overweight or obese women with PCOS, pooled liraglutide interventions alone or in combination modestly increased sex hormone-binding globulin versus control treatments.
In plain wordsIn overweight or obese women with PCOS, pooled liraglutide-alone or combination interventions modestly increased sex hormone-binding globulin versus controls.
Peptide
Liraglutide
Outcome
IncreaseSex hormone-binding globulin
Study
n: not reported in source
Comparator
Control treatments
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
modestly increased sex hormone-binding globulin levels.
3 context sentences(design, population, supporting numbers)
Summary · context
Compared with control treatments, liraglutide significantly increased menstrual frequency (g = 1.76; 95% CI [0.28, 3.24])
Summary · context
PubMed, Embase, the Cochrane Library, Scopus, Web of Science and ClinicalTrials.gov were systematically searched from inception to 31 May 2025 for randomized controlled trials (RCTs) comparing liraglutide (alone or in combination) with placebo, metformin or non-liraglutide active treatments in overw…
Summary · context
Seven RCTs comprising 330 women with PCOS were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4150893206
07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In overweight or obese women with PCOS, pooled liraglutide interventions were generally well tolerated, with mainly mild gastrointestinal adverse events.
In plain wordsIn overweight or obese women with PCOS, pooled liraglutide-alone or liraglutide-combination interventions were generally well tolerated, with mainly mild gastrointestinal symptoms.
Peptide
Liraglutide
Outcome
Not applicableGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Liraglutide was generally well tolerated, with adverse events consisting mainly of mild gastrointestinal symptoms.
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Embase, the Cochrane Library, Scopus, Web of Science and ClinicalTrials.gov were systematically searched from inception to 31 May 2025 for randomized controlled trials (RCTs) comparing liraglutide (alone or in combination) with placebo, metformin or non-liraglutide active treatments in overw…
Summary · context
Seven RCTs comprising 330 women with PCOS were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4150893207
08HumanNot a test of Liraglutide aloneSystematic reviewOther
In the review of liraglutide-alone or liraglutide-combination interventions in overweight or obese women with PCOS, ovulation outcomes could not be pooled because reporting was insufficient.
In plain wordsIn this review of liraglutide-alone or combination interventions in overweight or obese women with PCOS, ovulation results could not be pooled because reporting was insufficient.
Peptide
Liraglutide
Outcome
Not applicableOvulation meta-analysis pooling
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Reproductive outcomes such as ovulation and pregnancy could not be pooled due to insufficient reporting.
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Embase, the Cochrane Library, Scopus, Web of Science and ClinicalTrials.gov were systematically searched from inception to 31 May 2025 for randomized controlled trials (RCTs) comparing liraglutide (alone or in combination) with placebo, metformin or non-liraglutide active treatments in overw…
Summary · context
Seven RCTs comprising 330 women with PCOS were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4150893208
09HumanNot a test of Liraglutide aloneSystematic reviewOther
In the review of liraglutide-alone or liraglutide-combination interventions in overweight or obese women with PCOS, pregnancy outcomes could not be pooled because reporting was insufficient.
In plain wordsIn this review of liraglutide-alone or combination interventions in overweight or obese women with PCOS, pregnancy results could not be pooled because reporting was insufficient.
Peptide
Liraglutide
Outcome
Not applicablePregnancy meta-analysis pooling
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Reproductive outcomes such as ovulation and pregnancy could not be pooled due to insufficient reporting.
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Embase, the Cochrane Library, Scopus, Web of Science and ClinicalTrials.gov were systematically searched from inception to 31 May 2025 for randomized controlled trials (RCTs) comparing liraglutide (alone or in combination) with placebo, metformin or non-liraglutide active treatments in overw…
Summary · context
Seven RCTs comprising 330 women with PCOS were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4150893209

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.